The Pharmaceutical Journal
Vol 280 No 7498 p462
19 April 2008

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Three-year benefit in MS

Fingolimod, a novel immunomodulating agent, can maintain low relapse rates for three years in multiple sclerosis patients, results presented at the American Academy of Neurology annual meeting in Chicago, Illinois, this week suggest.

A previous study showed benefit up to six months (PJ, 16 September 2006, p331). In this new study more than two thirds of the 173 people who took part remained free of relapses after three years’ oral treatment with fingolimod, a sphingosine-1-phosphate receptor modulator.

In addition, 69 per cent remained free of disease activity and 75 per cent were free of new or newly enlarged lesions.